Memantine for prevention of migraine: a retrospective study of 60 cases
Open Access
- 24 September 2007
- journal article
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 8 (4) , 248-250
- https://doi.org/10.1007/s10194-007-0406-7
Abstract
The objective was to retrospectively characterise the efficacy of memantine as preventive therapy in a series of patients with frequent migraine. Patients in a university headache clinic completed a survey regarding their experience with memantine, and medical records were reviewed. All patients who received memantine as preventive therapy for migraine over a 15-month period were mailed surveys and consent forms for record review. Patients were treated with memantine beginning at a dose of 5 mg/day, increasing if needed by 5 mg/week up to 10 mg twice a day. The majority of patients (36 out of 54) treated with memantine for at least 2 months reported a significant reduction in estimated headache frequency, and improved function. Side effects were uncommon and generally mild. This limited retrospective case review suggests that memantine may be an effective preventive therapy for patients with frequent migraine. A prospective trial is warranted.Keywords
This publication has 7 references indexed in Scilit:
- Effects of Pan- and Subtype-Selective N-Methyl-d-aspartate Receptor Antagonists on Cortical Spreading Depression in the Rat: Therapeutic Potential for MigraineThe Journal of Pharmacology and Experimental Therapeutics, 2007
- The chemical biology of clinically tolerated NMDA receptor antagonistsJournal of Neurochemistry, 2006
- New insights into migraine pathophysiologyCurrent Opinion in Neurology, 2006
- Memantine Blocks α7* Nicotinic Acetylcholine Receptors More Potently Than N-Methyl-D-aspartate Receptors in Rat Hippocampal NeuronsThe Journal of Pharmacology and Experimental Therapeutics, 2005
- The N-methyl-d-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT3 receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive mannerNeuroscience Letters, 2001
- Memantine in severe dementia: results of the9M-best study (benefit and efficacy in severly demented patients during treatment with memantine)International Journal of Geriatric Psychiatry, 1999
- Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicityJournal of Neuroscience, 1992